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P-glycoprotein (P-gp) is the most intensively studied eukaryotic ATP binding cassette (ABC) transporter, due to its involvement in the multidrug
resistance phenotype of a number of cancers. In commonwithmost ABC transporters, P-gp is comprised of two transmembrane domains (TMDs) and
two nucleotide binding domains (NBD), the latter coupling ATP hydrolysis with substrate transport (efflux in the case of P-gp). Biochemical
investigations over the past twenty years have attempted to unlock mechanistic aspects of P-glycoprotein through scanning and site-directed
mutagenesis of both the TMDs and the NBDs. Contemporaneously, crystallographers have elucidated the atomic structure of numerous ABC
transporter NBDs, as well as the intact structure (i.e. NBDs and TMDs) of a distantly related ABC-exporter Sav1866. Significantly, the structure of
P-gp remains unknown, and only low resolution electron microscopy data exists. Within the current manuscript we employ crystallographic data
for homologous proteins, and a molecular model for P-gp, to perform a structural interpretation of the existing “mutagenesis database” for P-gp
NBDs. Consequently, this will enable testable predictions to be made that will result in further in-roads into our understanding of this clinically
important drug pump.
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The spectre of multidrug resistance continues to haunt the
treatment of cancer, as well as bacterial, viral and parasitic
infections [1]. One of the mechanisms contributing to cancer
Table 1
Conserved ABC transporter motifs in P-glycoprotein
Motif
name
Sequence P-gp residue Proposed function
N-half C-half
A-loop FxYPX 401 1044 Aromatic ring stacking
with adenosine
Walker-A GxSGCGKS 427–434 1070–1077 ATP binding pocket
formation
Gln-loop VSQEP 473–477 1116–1120 Inter-domain
communication role
X-loop TxVG{E/D}
{R/K}G
522–528 867–873 Inter-domain
communication role
Signature LSGGQ 531–536 1176–1181 Cross-dimer ATP binding
pocket formation
Walker-B ILLLDE 551–556 1196–1201 ATP binding pocket
formation
D-loop SALD 559–562 1204–1207 Cross-dimer interaction
His-loop IVIAH 583–587 1228–1232 ATP-dependent switch
region
For each motif we give the sequence location of the motif in each half of human
P-gp, the flanking sequence (x represents any amino acid) and the function of
each.
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ATP binding cassette (ABC) transporter family [1]. These pro-
teins are envisaged as a front-line mechanism contributing to
anti-cancer drug resistance, by limiting the intracellular accu-
mulation of cytotoxic drug and hence reducing the efficacy.
At least three human ABC transporters, namely P-glycoprotein
(P-gp; ABCB1 [2]), multidrug resistance associated protein 1
(MRP1;ABCC1 [3]) and breast cancer resistance protein (BCRP;
ABCG2 [4]), have been shown in vitro to have the capability to
efflux a structurally and mechanistically diverse range of anti-
cancer agents [5–7]. Additionally, the clinical impact of over-
expressing these three ABC transporters on the prognosis of
several tumour types has been documented [8].
ABC transporters are multidomain proteins and these do-
mains may be encoded by different genes. However, a common
minimum functional unit (at least for eukaryotic export ABC
transporters) seems to consist of two transmembrane domains
(TMDs), each of which contains multiple α-helices [9], and two
cytoplasmic nucleotide binding domains (NBDs) [10]. The
TMDs form substrate binding sites and provide a translocation
path across the membrane [11–13], whilst the NBDs bind and
hydrolyse ATP, the energy of which powers the drug export
process [14]. A panoply of experimental data for P-gp and
related ABC transporters supports the view that conformational
changes are transmitted between these four domains and that the
regulation of this allostery is crucial for correct overall protein
function [15–17].
The most intensively investigated of this triumvirate of drug
pumps is P-gp, which has now been studied for over three
decades [18]. A subset of these investigations has been aimed at
unlocking the molecular mechanism of P-gp, that is, to
determine which amino acids are central in the recognition
and transport of drugs and those which are critical for ATP
binding and hydrolysis to name two examples. Moreover,
studies aimed at determining how the two TMDs and the two
NBDs communicate with each other have been performed in
order to increase our understanding of conformational change
transmission [14]. The majority of these studies have relied on
site-directed or scanning mutagenesis to produce mutant
isoforms of the protein, which are then tested for inter alia
drug binding, drug transport, and ATPase activity (for
examples, see [19–23]). In the latter case activity is measured
both in the absence of drug, the so-called basal ATPase, and in
the presence of drug, the so-called drug stimulated ATPase.
In parallel with these investigations, there have been ad-
vances in our understanding of the structure of ABC proteins
[24–32]. Notably the major advances have been: i) the descrip-
tion at atomic resolution of the structure of an isolated NBD
[26], ii) the prediction [33] and then the structural confirmation
[29,34] of the correct interaction between a pair of NBDs [10]
and iii) the first determinations of the complete structures of
entire ABC transporters [25,27,35–37]. These exciting struc-
tural developments allow an interpretation of the massive
wealth of mutagenesis data that has appeared during the past
twenty years for P-gp. In the current review article, we focus on
the NBDs of P-gp and revisit the published mutagenesis data on
these. A broader account of the mutational analysis of ABCtransporters has been provided recently [38]. We will illustrate
how the interpretation of the effects of mutations on the NBDs
can in some instances be revised based upon the structural data,
and we provide an on-line resource which will grow in parallel
with future experimentation. Some candidate residues for muta-
tion are outlined in the final paragraphs.
2. The structure of the nucleotide binding domains and
their association into an ATP-dependent dimer
Within ABC transporter NBDs there are present several
sequence motifs (or even individual residues) which have a
higher degree of conservation than the rest of the domain [39].
At least 8 such sequences have been described (Table 1). Of
these, the Walker-A (GxxGxGK{S/T}, where x is any residue)
and Walker-B (θθθθDE, where θ is any hydrophobic residue;
note that for convenience we include the highly conserved
glutamate C-terminal to the aspartate in this consensus) are
present in many other classes of ATPases and are known to
make non-covalent interactions with the triphosphate moiety of
ATP, and to catalyse the hydrolysis of the γ-phosphate [40].
The other motifs are specific to ABC transporters, and several
other families of proteins which employ the ABC transporter
NBD as an energising module for other functional systems such
as DNA repair and translational control [34,41–44]. Of these
specific motifs the signature sequence, D-loop, X-loop and the
His-loop can be defined by conserved motifs (LSGGQ, SALD,
xVG{D/E}{K/R}G, and βθβμH respectively, where β is a
branched aliphatic residue, and μ is a hydrophilic residue),
whereas the Gln-loop and the A-loop are identified as having
a highly conserved residue (any aromatic in the case of the
A-loop) approximately 30 amino acids C-terminal and 20 amino
acids N-terminal to the Walker-A motif respectively. The func-
tions and importance of these sequences have been intensively
researched, and a structural corroboration has been possible in
some cases [39]. However, we are still considerably short of
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NBDs coordinates functionally with the other motifs and con-
tributes to the overall mechanism of P-gp.
The first glimpses into the structures of ABC transporters
came with the 1.5 Å structure of the NBD of the histidine
importer from S. typhimurium, HisP [26]. Since then, at least 20
NBD structures have been published [39] and there are several
dozens more deposited in the Protein Data Bank. The structure
of the single NBD is essentially composed of two sub-domains
[9,10,39]; firstly, an α/β sub-domain which shows some struc-
tural homology to the F1-ATPase and RecA structures and
contains four of the conserved motifs (Walker-A, Walker-B,
His-loop and A-loop; discussed below) present in all ABC
transporter NBDs. Secondly, a primarily α-helical sub-domain
exists, encompassing the signature motif, and including a region
with greater diversity between NBDs of ABC transporters of
unrelated function [39]. The exact orientation of the two sub-
domains (which is approximated by an L-shape) is influenced
by the nucleotide occupancy of the domain [39], and two further
conserved motifs (the D-loop and Gln-loop) are located at the
sub-domain interface.
The crystallization of NBDs from various ABC transporters
in a number of different dimeric associations led to an initial
confusion over the precise dimeric interaction of two NBDs
[10]. The use of selected mutant isoforms of several NBDs has
allowed this dimer interface to be unequivocally determined
now. The dimer is frequently likened to a sandwich, with nu-
cleotide being the filling between two NBDs. For example, the
NBD of rat TAP1 crystallized as a sandwich dimer when the
Walker-B C-terminal acidic aspartate was neutralized to aspa-
ragine [28], the equivalent mutation in MJ0796 produced the
same structural apposition [45] and an alternative mutation
(substitution of the conserved histidine of the His-loop with
alanine) produced the same conformation in the NBD of the
haemolysin transporter [32]. The apposition of nucleotide at the
NBD:NBD interface generates composite ATP binding sites
involving residues in the Walker-A and -B motifs of one NBD,
and the signature motif of the other NBD [29,43,46].
3. Structure of P-gp
Whilst there has been an explosion in the structural deter-
mination of NBDs, progress with P-gp has been at lower reso-
lution. In particular the electron microscopic studies of Ford et
al. have gradually improved in resolution from an initial 25 Å to
8–10 Å (although with loss of resolution in the plane perpen-
dicular to the membrane [15,47–49]). Even at this resolution it
remains difficult to map the constituent domains onto the
electron density with any certainty. This has necessitated the
building of structural homology models in order to underpin
biochemical and pharmacological investigations into the pump.
However, these have been primarily based upon three structures
for MsbA, all of which have subsequently been retracted due to
errors in crystallographic data miscalculation [50]. In light of the
need to recalculate the MsbA structures [50] it is worth explain-
ing that features of the NBD:NBD interface may be correctly
represented in these homology models (if built based upon thestructure of the S. typhimurium MsbA in the presence of ADP
and vanadate [51]). However, the details of the NBD:TMD and
TMD α-helical packing are likely to be incorrect [52–54]. Thus,
the advent of the structure of Sav1866 [25], a bacterial putative
multidrug exporter has enabled more realistic homology models
of P-gp to be constructed [55]. As a consequence we are able to
now consider the mutagenesis database for P-gp and correlate it
with our structural and functional understanding of this protein.
4. Approaches used in the site-directed and site-scanning
mutagenesis of P-gp NBDs
The extensive mutagenesis of the NBDs of P-gp does not
always have predictable outcomes. Whilst mutations in certain
of the most conserved regions may have a predictable effect,
there remain many mutations which can only be interpreted in
the light of structural data, and other mutations which can be
reinterpreted in the light of newer structural data. Before dis-
cussing these it is worth briefly diverting to consider the types of
experimental approach that have been used by several research
groups to probe the function of mutant isoforms of P-gp.
Within this review we have included analyses of mutations
that are made in one of three backgrounds. Two of these back-
grounds can be considered wild type (human MDR1 P-gp and
mouse MDR3 P-gp). The third is a mutant background in which
the seven endogenous cysteines of P-gp have been replaced by
alanine [56] or serine [57]. In each case the cysteine-less iso-
form has been characterized and shown to possess normal basal
and drug stimulated ATPase activity, to be fully functional for
transport [56,57], and to have a pharmacological profile essen-
tially indistinguishable from the wild type P-gp [57].
The characterization of mutations again broadly falls into
two distinct classes; those in which the protein was purified and
those in which it was not. In the latter case, typical experiments
to characterize the broad effect of mutation on protein function
are whole cell transport assays (which may be radioactivity or
fluorescence based), cell cytotoxicity experiments, functional
complementation, or membrane based assays such as cross-
linking and residue accessibility studies. Experimental studies
of purified protein (and in some instances reconstituted protein)
are by their nature able to discern more precisely the effect of
residue substitution. Reconstitution of the protein allows the
ATPase activity of the protein in both the basal state (no drug
substrate) and the drug stimulated state to be investigated, thus
reporting on the coupling of the NBDs with the events at the
TMDs. Additionally, the specific nucleotide occupancy may be
investigated as an experimental variable by examination of P-gp
in multiple conformational states including the resting -state (no
nucleotide bound), the ATP bound state (in the presence of
AMP-PNP, but see [39,58] for a discussion of caveats) and the
post-hydrolytic state (ADP.vanadate trapped conformation).
The use of radioactive, photoactive derivatives of ATP ([32P]-
labelled azido-ATP) has proved valuable in these endeavours.
Within the following discussion we will try to include salient
experimental details to enable comparison of similar functional
assays on mutant isoforms of the protein. In the ensuing
paragraphs we concern ourselves only with mutations made in
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the isolated NBDs.
5. Structural templates for interpretation of P-gp NBD
mutational analysis
Our structural (re)-interpretations of mutagenesis data
involve mapping residues onto two templates (Fig. 1). The
first is that for the bacterial exporter Sav1866, from S. aureus,
which has been solved to a resolution of 3.0 Å in the presence of
ADP, although the structure is believed to be equivalent to an
outward facing ATP bound state [25]. Sav1866 crystallizes as aFig. 1. Structural templates used to infer the role of residues within P-gp. a. Homolog
rendered in a ribbon representation with the NBDs in cyan (NBD1) and light green (
dotted lines. The TM helices and intracellular connecting loops of TMD1 are colou
yellow-green, ICL2 yellow, TM5 orange, TM6 red. b. Structure of the rat TAP NBD1
conserved sequence motifs highlighted as follows: aromatic-loop red; Walker-A oran
Asp-loop blue; His-loop magenta.homodimer with the two NBDs adopting a sandwich dimer
configuration. The important aspect of this structure for the
current interpretation is the “domain swapping” observed, i.e.
that the TMD of one Sav1866 monomer makes extensive
contacts through two intracellular linker regions (ICLs) to the
NBD of the opposite Sav1866 monomer [25]. Rather than use
the structure of Sav1866 itself we have used a model of P-gp
based upon the Sav1866 structure (Fig. 1a). The model is
described in full by O'Mara and Tieleman [55]. The second
structural data we employ is the high resolution structure of a rat
TAP1 NBD homodimer [28], in which each TAP1 bears an
Asp→Asn mutation at position 645, which is comparable to they model of human P-gp based upon the structure of Sav1866 [25]. The model is
NBD2) respectively. The approximate location of the membrane is indicated by
red as follows: TM1 magenta, TM2 blue, ICL1 cyan, TM3 bright green, TM4
homodimer [28]. The two NBDs are in different degrees of grey shading, with the
ge; Gln-loop yellow; X-loop dull green; signature bright green; Walker-B cyan;
Fig. 1 (continued ).
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motif (residues 556 and 1201 in P-gp). This structure was solved
to 2.0 Å resolution with two ATP molecules coordinated in the
sandwich dimer arrangement [28], and is employed as an inter-
pretative tool as it is the highest resolution NBD dimer structure,
is from an eukaryotic ABC transporter, and shares 45% sequence
identity in the NBDs with P-gp (Fig. 1b). A multiple sequence
alignment of the NBDs of Sav1866, human and mouse P-gp
(N- and C-terminal sequences) and rat TAP1 was constructed
with ClustalW [59], and was used without manual refinement
to determine equivalent residues for structural mapping purp-
oses (Fig. 2). These 6 sequences share between 36% (TAP1:
Sav1866) and 92% (human:mouse NBD1) sequence identity.
All structural mapping was done using RasTop as a visualiza-
tion aid, with further molecular structure diagrams generated
using MolScript [60].
For each mutant isoform we have prepared an entry in a table
(Supplementary Tables S1–S4) which defines the residue mu-
tated, indicates its conservation, the functional effect, the original
interpretation, relevant structural details obtained from mapping
onto TAP1 and a Sav1866-based P-gp model, and a revised
structural interpretation where appropriate. Several of these are
discussed in more detail in the following sub-sections. The
Supplementary Table and accompanying text is split into 3
comparable sub-tables, discussing mutations involved in ATP
binding/hydrolysis (Table S1), mutations at the NBD:NBD
interface (Table S2), and mutations at the NBD:TMD interface
(Table S3). This partitioning of the data is purely for convenience
as of course residues at the NBD:NBD interface may additionally
affect ATP binding and hydrolysis. A fourth table (Table S4)
consisting of mutations which either do not fit conveniently into
one of the other three tables, or which impart relatively littlemechanistic knowledge is also appended. All four tables will be
continuously updated at our website, http://www.nottingham.ac.
uk/∼mbzidk/P-gp%20Mutations.htm. Throughout the text we
use both the single letter and three letter amino acid codes, but
refer to mutations using the format X123Z to denote replacement
of residue X at position 123 with residue Z.
6. Mutations involved in conserved motifs critical for ATP
binding and hydrolysis (Table S1)
The majority of mutations that fall under this banner have
either predictable effects on ATP binding and/or hydrolysis, or
have been made in the light of early structural data (i.e.
subsequent to the publication of a monomeric NBD [26]) which
is substantiated by more recent data. For example, the recent
mutation of the conserved aromatic amino acid of the A-loop
produced data which was consistent with an absolute require-
ment for an aromatic residue (Phe or Tyr) at A-loop positions in
NBD1 and NBD2 for full ATPase activity and transport activity
[61,62]. Even substitution of the existing tyrosines with tryp-
tophans was only partially tolerated (a double Tyr→Trp mutant
was non-functional in transport assays) [61]. Although struc-
tural data (Fig. 3) clearly demonstrates that the aromatic ring
stacks in a π–π fashion with the adenine ring of bound nu-
cleotide [25,26,28], none of the investigations at this position
(within P-gp) has so far been able to demonstrate why ATP is
the preferred nucleotide substrate for P-gp. Although the indi-
vidual NBDs of P-gp can bind CTP and GTP [58], and mem-
brane vesicles isolated from P-gp over-expressing cells can
perform GTP-dependent drug transport at a rate approximately
75% that supported by ATP [63], the purified protein displays
only 7–12% activity when incubated with GTP, compared to
Fig. 2. Sequence alignment of the NBDs of human and mouse P-gp, Sav1866 and rat TAP1. Sequences were aligned by ClustalWand the multiple alignment was not
manually adjusted. Consensus motifs are highlighted as coloured in Fig. 1b.
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E. coli colicin transporter, CvaB, have shown that the amino
acids 2 and 3 residues downstream of the conserved aromatic
are determinants of nucleotide specificity [66]. Mutagenesis of
equivalent residues in the P-gp aromatic loops may be re-
quired to fully understand nucleotide specificity, although there
is no strong residue conservation with CvaB to guide mutant
selection.Fig. 3. Aromatic residue:nucleotide interactions in P-gp. The conserved
aromatic residue upstream of the Walker-A motif in the NBD forms a stacking
π–π interaction with bound nucleotide.Residues within the Walker-A motif have also been the
subject of intense mutagenesis activity, in particular the lysine
residues 433 and 1076. A general consensus to emerge from
these studies is that the Walker-A lysine is essential for ATP
hydrolysis, with even a mutation of this lysine at one of the
two NBDs preventing a single cycle of ATP hydrolysis in the
presence of vanadate (evidenced by the ability to trap ADP.
vanadate), whilst ATP binding was perturbed but not fully
prevented — depending to some extent on the substituted
residue [67–72]. As with the A-loop mutations these data can be
explained by the structural data on the isolated NBD, without
the requirement for detailed structural data on P-gp per se.
Two of the seven endogenous cysteine residues in human
P-gp (Cys 431, Cys 1074) have proved useful in mutational
analysis and cross-linking studies as they are positioned within
the Walker-A motif (Table 1). Two studies have proposed that
the Walker-A cysteine residues can be cross-linked to the op-
posite Walker-A motif [73,74], either through a direct disul-
phide between the two naturally occurring Walker-A cysteines
[74] or between the Walker-A cysteine of NBD2 and a G427C
Walker-A NBD1 mutation [73]. Examination of our structural
templates, which are both in a nucleotide bound configuration,
suggests that such a direct interaction is unlikely as the Cα
atoms of these residues are in excess of 35 Å apart (Table S1).
More recently, in the light of the NBD sandwich dimer, Loo et
al. have demonstrated that the Walker-A cysteine can be cross-
linked to a cysteine residue introduced within the opposite
signature motif (L1176C, [19]), 10 Å apart (Cα–Cα, Table S1).
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findings may lie in the temperature required to effect oxidative
cross-linking. Walker-A cross-linking to the signature motif
could be effected at 4 °C, whereas the Walker-A:Walker-A
cross-linking required 37 °C [19,73,74]. For the Walker-A
motifs to be sufficiently close to each other during the catalytic
cycle (which of course occurs at 37 °C) would still require a
dramatic change in the NBD:NBD orientation. It is also worthy
of mention here, that in addition to being involved in cross-
linking studies, it has been firmly demonstrated that these
Walker-A cysteine residues are the site of interaction with a
number of sulphydryl reactive, non-specific inhibitors includ-
ing N-ethylmaleimide (NEM), 4-chloro-7-nitro-1,2,3-benzox-
adiazole (NBD-Cl), and 2-(4-maleimidylanilino)-naphthalene-
6-sulfonic acid (MIANS), and that these reagents are able to
inhibit P-gp ATPase in an ATP-protected manner [58,71,74–77].
Of these, MIANS has a linear length of at least 16 Å [78],
suggesting that during the catalytic cycle there is a significant
opening of the NBD dimer. Inhibition studies with larger male-
imides may shed, complementary, further information on this
separation (see Fig. 4).
Finally, within this section we consider the mutations made to
the conserved Walker-B acidic amino acids Glu 556 in P-gp
NBD1 andGlu 1201 in NBD2. This residue is often referred to as
the “catalytic carboxylate”, although Schmitt et al. distinguish
between this residue as a general base and the possibility of
substrate-assisted catalysis [32]. Neutralization of the acidic
residue has, in studies on distinct ABC transporters, resulted in
the detection of nucleotide bound tightly (“occluded”) by the
mutant protein [22,23,28,45,79]. Discounting the experimental
trapping of ADP with vanadate, this tight binding of nucleotide
(reported Kd for ATP is 9 μM in the occluded state [22]), is not
seen in un-mutated P-gp (Kd for ATP is 0.5 mM [80]), and has
prompted detailed investigations to focus on these residues.
Single mutations (E552Q or E1197Q) in mouse MDR3 produced
isoforms thatwere inactive in a functional complementation assay
(export of FK506 from S. cerevisiae) [81]. Additionally, the
purified mutant isoforms displayed undetectable basal and drug
stimulated ATPase activities [81]. However, they retained the
ability to trap ADP.vanadate following incubation with Mg.ATP,
indicating that the hydrolysis of a single ATP molecule was still
occurring, but that cycles of ATP hydrolysis were being impaired,Table 2
The NBD:NBD sandwich dimer interface
NBD1 residues Location NBD2 residues Location
404–407 a Post A-loop 1161–1164 Pre-signature
427–431 b Walker-A 1174–1179 Signature
473–477 Gln-loop 1117–1121 Gln-loop
556–564 D-loop 1201–1208 D-loop
586–590 c His-loop 1204–1207 D-loop
627–630 C-terminus 1273–1276 C-terminus
The other interactions are essentially symmetrical i.e. between the same motif within N
which is based upon the Sav1866 structure in the presence of ADP [25].
a The equivalent NBD2:NBD1 interaction is residues 1047–1050 being close to
b The equivalent NBD2:NBD1 interaction is residues 1070–1074 being close to
c The equivalent NBD2:NBD1 interaction is residues 1231–1234 being close topotentially due to abrogated release of Mg.ADP [81]. A slightly
different interpretation resulted from studies of double mutants in
purified mouseMDR3 containing E→Q, E→A, E→D and E→K
mutations at the equivalent Walker-B position [22] and from
studies of human P-gpwith a double E→Qmutation [82]. In these
studies the double mutants showed a very low, but P-gp specific,
ATPase activity (up to 1000-fold lower than wild type), which
differed depending on the mutation introduced (e.g. E→Amutant
was 2.5-fold more active than an E→K mutation) [22]. Loss of
even a single methyl group from the Glu sidechain rendered P-gp
several hundred fold less active than wild type demonstrating
both that length of the sidechain and its chemistry is essential [22].
Detailed analysis of ATP binding in the presence of vanadate, and
analysis of the bound species by thin layer chromatography
provided an explanation for the effects of Glu mutations on P-gp
[22,82]. Rather than being the result of impaired second cycle
ATP hydrolysis, it was concluded that transition state formation
was altered in the mutants, presumably due to the failure to co-
ordinate nucleotide correctly, the mutants being able to stably trap
ATP in a vanadate independent manner with a 1:1 molar stoi-
chiometry [22,82]. An important question pertaining to these
mutants is whether the occlusion of ATP represents a genuine step
in the catalytic cycle of P-gp, or whether it is a side-effect of the
mutations. Recent investigations support the occluded state being
a true step in the catalytic cycle (Fig. 4 schematic). Firstly,
residues which co-ordinate Mg.ATP prior to hydrolysis (e.g.
Walker-A lysine and serine; Table S1) also impact upon ATP
occlusion [23]. Secondly, broadly speaking, the basic commu-
nication between NBD and TMD is unaltered by the E→A
mutations, with drug stimulation of ATP occlusion observed [23].
Demonstration of the occluded nucleotide in wild type P-gp
would serve as additional evidence for the schematic in Fig. 4.
7. Mutations at the NBD:NBD interface (Table S2)
By definition within this section we mean the classical sand-
wich dimer NBD:NBD interface that has been observed struc-
turally now in several studies of isolated NBDs and intact ABC
transporters [25,29,32,34]. Essentially there are 6 points of in-
teraction between the two NBDs (Table 2) and several of the
mutations that localize to these interfaces directly impact upon
ATP hydrolysis and/or binding.Closest approach Cα–Cα (Å) Closest approach sidechain (Å)
5.5 2.2 (Pro 1162:Glu 406)
5.3 2.8 (Ser 429:Gly 1179)
8.8 5.3 (Glu 476:Glu 1119)
5.4 4.9 (Ser 559:Ser 1204)
4.7 3.6 (His 587:Asp 1207)
8.7 5.7 (Thr 630:Ala 1275)
BD1 and NBD2. Distances are determined from the model of O'Mara et al. [55],
residues 514–518.
residues 529–534.
residues 560–563.
Fig. 4. Binding, and asymmetric occlusion of nucleotide in the catalytic cycle of P-gp. The two NBDs of P-gp (L-shapes) are each envisaged to bind nucleotide weakly
initially and symmetrically [80], and then to progress into an asymmetric configuration in which one nucleotide is tightly bound/occluded and the other remains weakly
bound. The asymmetry emerging after an initial symmetrical event is inferred [23] but supported by molecular dynamics simulations of BtuCD andMJ0796 [102,104].
The occluded nucleotide is committed to hydrolysis and the asymmetry in NBD function is likely to be imparted for subsequent cycles. The extent of NBD dimer
opening remains unclear but three inhibitors of P-gp ATPase activity which interact with the Walker-A cysteine residues are depicted with their molecular sizes. Either
the separation between the two NBDs prior to formation of the occluded state (r1), or subsequent to ADP release (r2), must approach the size of the largest of these,
MIANS, at 16 Å [78]. The affinity for drug substrate is depicted around the perimeter with transitions occurring between configurations I and III and subsequent to
configuration IV [108].
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been made since the description of the sandwich dimer and the
data already has a structural interpretation that would not differ
from one presented here. For instance, several pairs of residues
in the Walker-A:signature motif interface are sufficiently close
that, when mutated to cysteine, they can be cross-linked at
temperatures that would not necessarily support high rates of
ATP hydrolysis [19]. Structurally these two regions are as close
as 2.8 Å apart in a Sav1866 based model of P-gp [55] and this
ability to be cross-linked is therefore to be anticipated.
However, there are some mutations that do bear further
consideration. Firstly, we can revisit residues in the loop imme-
diately C-terminal to the Walker-B motif, known as the D-loop,
due to the presence of a conserved aspartic acid, 6 amino acids
downstream from the “catalytic carboxylate" (Fig. 2). The
neutralization of this amino acid in either half of mouse P-gp
produced a protein that had a severe overall functional impe-
diment, and 5- to 10-fold reduced ATPase activity compared to
wild type [81]. However, near normal drug stimulation of
ATPase activity was observed [81], suggesting that the residue
is not contributing to NBD:TMD interactions. Consistent with
this, it is clear from analysis of our structural templates that the
D-loop makes very close contact with the His-loop and the
Walker-A motif of the opposite NBD (Fig. 5a, Table 2), al-though comparison of NBD structures shows the D-loop to be
conformationally variable [83]. We note that the two bound
nucleotides are linked by as few as 7 amino acids; i.e. bound
nucleotide at NBD1 is coordinated by Walker-B glutamate
(residue 556), 6 amino acids C-terminal to this, the D-loop
aspartate (Asp 562) is in direct contact (b4 Å) with the His-loop
of NBD2 (His 1232), which itself interacts with bound nucleo-
tide at NBD2. This apposition suggests that the reduction in
overall ATPase activity is due to impaired NBD:NBD commu-
nication, potentially involving a direct charge:charge interaction
with the “switch histidine” residue [32,39].
We also consider an alternative interpretation for mutations
made to the second glycine of the signature motif (residues 534
and 1179; Fig. 5b). The consecutive glycine residues in the
signature are generally considered to be conserved on structural
grounds, the flexibility of the glycine backbone being a require-
ment to maintain the initial α-helical turn of the long post-
signature motif α-helix (α5). That is, the glycine residues are
conserved because they are intrinsic to the structure of the NBD.
Indeed, mutation of this residue to either aspartic acid, serine or
valine abrogates ATPase activity (and in some instances expres-
sion level) [84,85]. Examination of a P-gp model based upon
the Sav1866 structure indicates that three alternative explana-
tions can be considered for these effects. Firstly, as theorized in
384 J. Lawson et al. / Biochimica et Biophysica Acta 1778 (2008) 376–391the literature, the glycine may be required for intrinsic structural
integrity of the NBD. The occurrence of two glycine residues at
the 1st and 2nd positions of an α-helix is rare, and positional
preference mutagenesis studies indicate that glycine at the 1st or
2nd position is unfavourable [86]. It therefore seems unlikely
that a conserved di-glycine within the first turn of α-helix has aFig. 5. Putative NBD:NBD interactions in P-glycoprotein. a. Interaction of the D-loop
from NBD1 to NBD2. The two ADPmolecules are indicated as belonging to NBD1 o
extension to the Walker-B motif (the D-loop) of NBD1 bridges the NBD:NBD interf
bound at this NBD. The equivalent Walker-B and D-loop from NBD2 and His-loop f
the D-loop serine residues (Table 2) shown in ball-and-stick format. b. The conser
implications. The signature motif is shown in a ribbon representation with the sandwic
of the signature motif suggests a role in coordination of ATP. The unusual siting o
conformational integrity of the entire X-loop and signature motif region, with implica
and ribbon colours for the highlighted motifs mirror those in Fig. 1b.structural role. Secondly, the residue may have an indirect role
to play in the hydrolysis of ATP, its nitrogen atom being posi-
tioned just 3 Å from the γ-phosphate of the bound ATP [28].
Thirdly, there may be an extrinsic (i.e. inter-domain) structural
role for the glycine residues due to their proximity to the TMDs.
The structural perturbation caused by mutation of the glycineof one NBD with the His-loop of the opposite NBD provides an allosteric span
r NBD2 depending on whichWalker-B motif is proximal to them. The C-terminal
ace and contacts the His-loop of NBD2, which itself is interacting with the ADP
rom NBD1 are shown in a backbone trace for clarity, with the close approach of
ved glycine residues of the signature motif may have structural and functional
hed ADP in ball-and-stick. The proximity of the N-atoms of the glycine residues
f two glycines at the N-terminus of an α-helix lends credence to a role in the
tions for the interaction with the opposite TMD, through the ICL1 (cyan). Stick
Fig. 5 (continued ).
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action that occurs between the α4″–α5 linker region with the
intracellular loop between TM α-helices 2 and 3 (or 8 and 9)
that forms part of the NBD:TMD interface [25]. This interaction
is between NDB1 and TMD2 (or vice versa) and leads to
reasoning that mutations in the signature motif may actually
affect drug stimulated ATPase activity. Certainly, this is con-
sistent with the experimental findings [84,85].
Finally, it is worth briefly revisiting a residue that was em-
ployed in a cysteine-scanning mutagenesis screen to document
the accessibility residues within P-gp NBD1 [87]. Lysine 515,
whichwhenmutated to cysteine is accessible to biotinmaleimide
in permeabilized cells, is located N-terminal to the signature
motif and is in close apposition to two loops in the oppositeTable 3
The TMD:NBD interface in P-gp
NBD residues Region of the NBD TMD residues Region of
442–445 (1085–1088) Post Walker-A 157–161 (798–802) ICL1
442–445 (1085–1088) Post Walker-A 907–913 (262–268) ICL2
478–483 (1121–1126) Post Gln-loop 899–903 (256–260) ICL2
490–493 (1133–1136) Helical domain 905–911 (262–268) ICL2
524–528 (1167–1171) X-loop 805–809 (164–168) ICL1
For each TMD:NBD contact region the residues contributing to the interaction are g
in parenthesis in columns 1 and 3. Distances are determined from the model of O'M
ADP [25].NBD, just C-terminal to the A-loop, and beyond the final con-
served motif (the His-loop) in the NBD. The function of this
single cysteine isoform in a whole cell transport assay was
unaffected [87] but our structural analysis places this residue at
the NBD:NBD interface and indicates that further mutagenesis at
this part of the interface may identify the existence of key
functional interactions contributing to NBD:NBD co-operativity.
One issue that continues to emerge from such studies is the
degree to which the NBDs of P-gp are functionally symmetric
[88,89]. Clearly this issue may not even be resolved if we have a
structure of P-gp as structural asymmetry within its NBDs is to
be expected as they are only 60% identical at the amino acid
level. A rational explanation is that, if there is a functional
asymmetry within the NBDs of P-gp, it may be rather more
subtle than for instance the asymmetry displayed by the two
halves of the TAP transporter, the two homologous halves of
MRP1 and the two homologous halves of the cystic fibrosis
conductance transmembrane regulator (CFTR) [90–92]. In
these latter instances functional asymmetry might be anticipated
by analysis of the key sequence motifs and the NBD sandwich
dimer. As Gaudet have pointed out for TAP1/2 for example,
only one of the two ATP binding sites formed by dimerization
of TAP1 and TAP2 presents what might be called a consensus
ABC transporter ATPase site. The other contains substitutions
as both the Walker-B and the His-loop which could render this
site less/non-functional [28]. In contrast, P-gp contains all the
key sequence elements necessary to have two consensus ABC
ATPase sites (Fig. 2).
8. Mutations at the NBD:TMD interface (Table S3)
Residues that have been mutated in P-gp studies can now be
more reliably interpreted if they have an effect on NBD:TMD
coupling, due to the advances made in understanding intact
ABC exporters [25]. This interface could not be reliably deter-
mined from previous structures of NBD dimers, or from at-
tempts to use the ABC importer structures as templates for
understanding domain:domain interaction in P-gp, such is the
low structural conservation between ABC exporters and im-
porters in this region [25,27,36]. Additionally, mapping onto the
initial structures of MsbA is also no longer justified, but the
revised structures will enable a comparison to be made with the
interpretations that result from consideration of a Sav1866
based model of P-gp [55]. Among the many novel observations
in the Sav1866 structure was the close contact between residuesthe TMD Closest approach Cα–Cα (Å) Closest approach sidechain (Å)
6.4 3.1 (Tyr 444:Gly 161)
8.3 4.0 (Leu 443:Val 908)
6.2 2.1 (Phe 480:Glu 899)
7.7 1.5 (Tyr 490: Leu 910)
5.0 3.2 (Gly 525:Asp 805)
iven for one NBD:TMD interface, with the opposite, equivalent interface given
ara et al. [55], which is based upon the Sav1866 structure in the presence of
386 J. Lawson et al. / Biochimica et Biophysica Acta 1778 (2008) 376–391in TMD1 and NBD2 and vice versa (Table 3). The most striking
mapping of residues at the NBD:TMD interface comes from a
recent cross-linking study of P-gp, designed to test whether the
domain interaction observed in Sav1866 [25] is also apparent in
P-gp [93]. Residues 443 (just a few amino acids after the end ofFig. 6. Proposed interactions between the NBD and TMD of P-glycoprotein. a. Cros
feature of P-gp. Residue 443 in NBD1 can be cross-linked to residue 909 following m
representation of the packing of Tyr 490 against the sidechains of residues in ICL2. Ty
opposite intracellular helix. The loop bearing Tyr 490 is shown in cyan in cartoon repr
elements are coloured green, yellow and orange respectively. c. The ERGA sequen
through the 1st intracellular coupling loop. The intracellular extensions to TM helices
X-loop of the opposite NBD. The ERGA sequence is shown in ball-and-stick reprethe Walker-A motif) and 909 (in the intracellular loop between
TM helix 8 and 9) in a cysteine-less version of P-gp were
mutated to cysteine and were shown to form a cross-link in the
presence of various bifunctional maleimides [93]. Similarly,
residue 474, immediately N-terminal to the Gln-loop could bes-linking provides evidence that the domain swapping observed in Sav1866 is a
utation to cysteine (cyan pair) as can residues 474 and 905 (red pair). b. Spacefill
rosine 490, the equivalent residue to Phe 508 in CFTR is in close proximity to the
esentation, with Tyr 490 itself rendered as spacefill. The TM10, ICL2, and TM11
ce of one NBD, which is part of the X-loop interacts with the opposite TMD,
8 and 9 and their connecting region (ICL1) are shown in cartoon fashion, as is the
sentation.
387J. Lawson et al. / Biochimica et Biophysica Acta 1778 (2008) 376–391cross-linked to residue 905 when both were mutated to cysteine
[93] (Fig. 6a). The fact that cross-linking was observed with
short spacer-length reagents indicates that the residues are
proximal in the structure — providing credence that P-gp has
the same domain architecture as that observed in Sav1866 [93].
Tyrosine 490 has been discussed in relation to P-gp due to its
analogy with the common cystic fibrosis mutation, deletion of
Phe 508. This mutation in CFTR causes defective synthesis and
trafficking of the protein [94]. Introduction of a single amino acid
deletion at Tyr 490 also showed an important role in the normal
trafficking and function of P-gp [95,96]. Structural analysis of
tyrosine 490, which resides in NBD1, shows a striking proximity
to the 2nd intracellular coupling helix of the opposite NBD, i.e.
the region connecting TM helices 10 and 11 in a P-gp model
[25,55], and is therefore a point of interaction between NBD and
TMD (Fig. 6b). On closer inspection, tyrosine 490 is seen to
contact two residues in the coupling helix, Thr 906 and Leu 910,
as well as being within 4 Å of other residues in the 906–916
region. These residues evidently form a “pocket” into which Tyr
490 appears to fit tightly (Fig. 6b). The disruption of this tight
NBD:TMD interaction may well correlate with the experimental
data showing reduced expression of the protein [95,96],
presumably due to significant effects on the folding pathway of
P-gp. Notably, this tyrosine residue is conserved in both NBDs of
human and mouse P-gp as well as in TAP1 (Fig. 2).
The domain swapping evident in Sav1866 also occurs be-
tween the intracellular linker between TM α-helices 4 and 5
(ICL2) and stretches of residues in the opposite NBD within
what is known as the X-loop. Remarkably, evidence of the
importance of this stretch of residues has been in the literature
for over a decade. Beaudet et al., comparing the sequence of the
N- and C-terminal NBDs of mouse MDR3 demonstrated that
substitution of residues 522–525 (ERGA; equivalent residue
numbers are 526–529 in human P-gp) from NBD1 with resi-
dues 1167–1170 from NBD2 (DKGT, 1171–1174 in human
P-gp) led to drastic alterations in the ability to confer resistance
to several anti-cancer drugs, and the ability to complement the
Ste6 transporter in S. cerevisiae [97]. The structure of Sav1866
[25] now shows that these residues are in contact with residues
in ICL1 reinforcing the observation that specific residues
within the X-loop of NBD 1 are required for productive NBD:
TMD interactions [97,98] (Fig. 6c). In contrast, a further resi-
due that could not be substituted between NBD1 and NBD2 in
mouse MDR3 (Thr 578, Thr 582 in P-gp) is not at a NBD:
TMD boundary, and no explanation for this effect is apparent
from examination of the structural data.Fig. 7. The Gln-loop may be involved in multiple allosteric processes within
P-gp. a. The Gln-loop of one NBD is capable of interactions with bound
nucleotide, the opposite Gln-loop and with the 2nd ICL of the opposite TMD.
The conserved glutamines (475 and 1118) are shown in spacefill representa-
tion, together with the closest amino acid in the opposite ICL (arginines 262
and 905). The TM helices preceding (TM4/10, green) and following (TM5/11,
orange) the intracellular loop (yellow) are shown in ribbon representation. The
rest of the Gln-loop and the bound nucleotide are in ball-and-stick configu-
ration. One of the ADP molecules lies in front of the plane in this view, and
the other lies behind the plane. b. Rotation through 90° allows clearer
inspection of the possible interactions. For clarity, only Q1118, R262 and one
nucleotide are shown.Several further residues mutated to cysteine by Blott et al. [87]
reinforce just how functionally malleable the TMD:NBD inter-
facemust be. Ser 474 andAla 529 can both bemutated to cysteine
without loss of overall transport function, and both have inter-
domain interactions of less than 5.0 Å with residues in the TMD.
The final NBD loop we discuss is the Gln-loop, the epony-
mous glutamine of which is almost strictly conserved in ABC
transporters [10]. Urbatsch et al. described the results of the
388 J. Lawson et al. / Biochimica et Biophysica Acta 1778 (2008) 376–391single mutants of residues Q475 and Q1118 to either a gluta-
mate or an alanine residue [89]. The mutations were seen to
affect the fold-simulation of ATPase activity by certain drugs,
with Q→A mutations more severely disrupted compared to
Q→E mutants, implying a role for this residue in TMD:NBD
communication [89], consistent with predictions from mole-
cular dynamics simulations of HisP [99,100]. In agreement
with this, the location of residues Q475 and Q1118 in our
Sav1866 based homology model is significantly close (less
than 6 Å) to the sidechains of arginines 905 and 262
respectively, in the ICL2 (Fig. 7). However, two alternative
interpretations also present themselves. The first is correlated
with the observations that the experimental mutations caused a
10-fold reduction in the basal ATPase activity (i.e. the activity in
the absence of drug substrate). This activity is believed to be due
to NBD:NBD communication only [101], and intriguingly the
two Gln residues lie close to the NBD:NBD boundary as well.
Indeed, the adjacent glutamate residues are as close at 6 Å
indicating that residues in the Gln-loop could contribute to NBD:
NBD interactions as well. A further role for the Gln-loop is in the
direct interaction with nucleotide as the residue is also ca. 6 Å
from bound triphosphate nucleotide [26]. Again a disruption of
the basal ATPase activity following mutation of the conserved
Gln would be consistent with this hypothesis. It seems that the
Gln-loop (which has so far escaped much experimental muta-
genesis) may be able to play functional roles in intra-domain
communication (i.e. the interaction with ATP bound to the same
NBD), inter-domain NBD:NBD communication and inter-
domain NBD:TMD communication.
9. Perspectives
There is no doubt that mutagenesis still has a significant role
to play in determining the mechanism of P-glycoprotein, and by
inference, other ABC transporters. There is sometimes a ten-
dency to dismiss the results of site-directed mutagenesis as
being due to a gross disruption to the protein structure, rather
than a specific effect on protein function. However, we have not
felt that this is necessary in the current work — most of the
mutations we have analysed have effects that can be rationalised
in terms of protein structural models. Moreover, the accumulat-
ing structural data on related proteins now enables both a more
targeted mutagenesis approach and a more rational interpreta-
tion of existing and new mutagenesis data. In particular, the
structural data on Sav1866 [25] and the revised MsbA structures
[115] will enable much mutagenesis at the NBD:TMD interface.
In addition, the emergence of structural data for ABC trans-
porters at different stages of the catalytic cycle may enable
further investigations of residues at the NBD:NBD interface.
We have highlighted here at least two regions (the Gln-loop and
the His-loop), mutations within which and proximal to, may
continue to yield mechanistic insights in P-glycoprotein func-
tion. Unequivocal interpretations may still be a rarity, particu-
larly when a mutation affects the communication between
domains within the transporter. In order to redress this we need
to provide a fully structural and mechanistic understanding of
P-gp by using a full arsenal of biochemical and biophysicaltechniques. Electron microscopy has pushed our understanding
of P-gp structure to almost secondary structural resolution and
has enabled the protein to be imaged in the presence and
absence of nucleotide [47]. Combining this data with emerging
crystallographic data on related ABC transporters [25] may
soon provide homology models for P-gp that are a good first
approximation to structures at different stages of the catalytic
cycle. Similarly, the deployment of molecular dynamics simu-
lations may be able to bridge the gulf between static structural
data/models and the changes in protein conformation and inter-
domain interfaces that are proposed to be relevant to P-gp
function [102–104]. Such dynamic changes may be further
explored by using electron paramagnetic resonance (EPR) and
solid state NMR spectroscopy. One EPR study for P-gp has
been reported [105] and several exist for MsbA [106,107].
The interpretation of EPR data, in terms of its ability to report
on local protein dynamics will undoubtedly complement and
make a considerable addition to our understanding of this
protein. For example, although mutations in the Walker-A
motif may seem to be fully explored, EPR spectroscopy could
reveal the changes occurring at the NBD:NBD interface in
terms of residue exposure, local polarity and local conforma-
tional flexibility.
So the current body of data we have analysed here cannot in
isolation explain the catalytic mechanism of P-gp and the
accompanying changes in inter-domain interaction. However,
we hope that with this analysis we have provided a useful
synopsis of the field and that the growing database of P-gp NBD
mutations may continue to spark further investigations.
10. Note added in proof
The structures of MsbA have been republished [115]. A full
comparison of these structures will appear at the NBD mutation
database website. The existence of an occluded nucleotide state
in wild type P-gp has been recently documented [116] adding
further credence to the model in Fig. 4.
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